Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...

Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...

Opthea and Uni­ty Biotech­nol­o­gy, which are both de­vel­op­ing new drugs for eye dis­eases, were un­able to beat or match afliber­cept, the stan­dard-of-care treat­ment that Re­gen ...

The plaintiff alleges that the defendants failed to disclose to investors that Regeneron paid credit card fees to distributors on the condition that distributors did not charge Eylea customers ...

It’s a great day for Regeneron as Unity is the second biotech to report a miss against its eye injection. Just this morning, Australia-based Opthea’s asset failed to match Eylea in a phase 3 ...

Atea had been evaluating a 2-mg dose of sozinibercept every four or eight weeks in combination with Regeneron’s blockbuster VEGF inhibitor Eylea in patients with wet age-related macular ...

GlobalData is the parent company of Clinical Trials Arena. Elsewhere in the WetAMD market, Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of its Eylea HD ...

Google lets you track devices using the Find My Device network like Apple but now this feature is able to let you locate people as well. Yes, the whole Device part of Google’s Find My has changed with ...

Boston Scientific makes surgical devices and medical equipment to treat ... due to wholesaler destocking. Regeneron Pharmaceuticals makes drugs to treat eye diseases, allergies, inflammation ...

Contributors to performance Boston Scientific makes surgical devices and medical equipment ... due to wholesaler destocking. Regeneron Pharmaceuticals makes drugs to treat eye diseases, allergies ...

We have an update on the One UI 7 rollout and it’s good news this time – the press release from Samsung Singapore lists more devices that will be updated to the latest Samsung software.

Achmea Investment Management B.V. significantly reduced its position in Regeneron Pharmaceuticals by 90.5% in the fourth quarter. After selling 17,567 shares, Achmea now holds only 1,841 shares of the ...